Summary
As information on the absorption kinetics and local degradation of infused insulin is relevant to programming strategies for continuous subcutaneous insulin infusion, we examined the time relationship of systemic insulin appearance and quantitated subcutaneous degradation during a near-basal rate of continuous subcutaneous insulin infusion in five insulin-dependent diabetic patients. Plasma free insulin was monitored for 8 h during and 3 h after a subcutaneous (abdominal wall) infusion of neutral insulin at 2.4 U/h. An identical intravenous infusion (2–4 h) was given on a separate occasion. Plateau levels of free insulin were not significantly different during the subcutaneous (37±8 mU/l) and intravenous (40±7 mU/l) infusions. Fitting of the free insulin data to our two-pool model of the subcutaneous space gave a mean estimate of 9.2 units insulin (= 3.8 h infusion) for the subcutaneous depot after 8 h. Model estimates of systemic insulin appearance, as a percentage of subcutaneous infusion rate, were 59% and 93% after 4 and 8 h respectively, and 76% 2 h after cessation of infusion. In insulin-dependent diabetic patients subcutaneous degradation of infused insulin is negligible but local accumulation in the subcutaneous space is considerable. The delay in absorption has important clinical implications for interruption and resumption of continuous subcutaneous insulin infusion and also for programming of variable basal rates.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Felig P, Bergman M (1982) Intensive ambulatory treatment of insulin-dependent diabetes. Ann Intern Med 97: 225–230
Chisholm DJ, Kraegen EW, Zelenka GS (1981) Programming of insulin delivery with meals during subcutaneous insulin infusion. Diabetes Care 4: 265–268
Kraegen EW, Chisholm DJ (1984) Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies. Diabetologia 26: 208–213
Campbell LV, Kraegen EW, Meler H, Lazarus L (1979) Hormonal responses to insulin infusion in diabetes mellitus. Diabetologia 16: 359–364
Kraegen EW, Chisholm DJ, Hewett MJ (1983) Comparison of plateau insulin levels achieved by intravenous or subcutaneous insulin infusion: evidence for low rates of subcutaneous degradation. Diabetes Care 6: 118–121
Kraegen EW, Lazarus L, Meler H, Campbell LV, Chia YO (1979) Hormonal responses to insulin infusion in diabetes mellitus. Diabetologia 16: 359–364
Desbuquois B, Aubach GD (1971) Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33: 732–738
Heding LG (1975) Radioimmunological determinations of human C-peptide in serum. Diabetologia 11: 541–548
McIntosh JEA, McIntosh RP (1980) Mathematical modelling and computers in endocrinology. Springer, Berlin Heidelberg New York
Kobayashi T, Sawano S, Itoh T, Kosaka K, Hirayama H, Kasuya Y (1983) The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes 32: 331–336
Lauritzen T, Pramming S, Deckert T, Binder C (1983) Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 24: 326–329
Binder C (1969) Absorption of injected insulin. Acta Pharmacol Toxicol (Copenh) 27 (Suppl 2): 1–84
Stevenson RW, Tsakok TI, Parsons JA (1980) Matched glucose responses to insulin administered subcutaneously and intravenously. Evidence for subcutaneous inactivation of insulin. Diabetologia 18: 423–426
Berger M, Halban PA, Müller WA, Offord RE, Renold AE, Vranic M (1978) Mobilization of subcutaneously injected tritiated insulin in rats: effects of muscular exercise. Diabetologia 15: 133–140
Berger M, Halban PA, Girardier L, Seydoux J, Offord RE, Renold AE (1979) Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at the injection site. Diabetologia 17: 97–99
Duckworth WC, Kitabchi AE (1981) Insulin metabolism and degradation. Endocr Rev 2: 210–232
Guerra SO, Kitabchi AE (1976) Comparison of the effectiveness of various routes of insulin injection: insulin levels and glucose response in normal subjects. J Clin Endocrinol Metab 42: 869–874
Owens DR, Jones MK, Hayes TM, Heding LG, Alberti KGMM, Home PD, Burrin JM (1981) Comparative study of subcutaneous, intramuscular and intravenous administration of human insulin. Lancet 2: 118–121
Waldhäusl WK, Bratusch-Marrain PR, Vierhapper H, Nowotny P (1983) Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man. Metabolism 32: 478–485
Friedenberg GR, White N, Cataland S, O'Dousio TM, Sofos JF, Santiago JV (1981) Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. N Engl J Med 305: 363–368
Keller U, Schnell H, Sonnenberg GE, Gerber PPG, Stauffacher W (1983) Role of glucagon in enhancing ketone body production in ketotic diabetic man. Diabetes 32: 387–391
Krzentowski G, Scheen A, Castillo M, Luyckz AS, Lefebvre PJ (1983) A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 24: 314–318
Mecklenburg R, Sannar C, Becker N, Benson J, Benson E, Brazel P, Fredlund P, Metz R, Nielsen R (1983) Frequency of complications associated with insulin pump therapy: report of experience with 198 patients. Diabetes 32 [Suppl 1] 35 A
Peden NR, McKendry JBR, Braaten JT (1983) Acute uncontrolled diabetes during long term subcutaneous insulin infusion. Diabetes 32 [Suppl 1] 36 A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chisholm, D.J., Kraegen, E.W., Hewett, M.J. et al. Low subcutaneous degradation and slow absorption of insulin in insulin-dependent diabetic patients during continuous subcutaneous insulin infusion at basal rate. Diabetologia 27, 238–241 (1984). https://doi.org/10.1007/BF00273813
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00273813